ADELIS. Discover the new world of cfDNA

Non-invasive prenatal testing using cell-free DNA analysis for fetal abnormality screening. Supports safe assessment of fetal health during pregnancy.

Cell-free DNA (cfDNA) liquid biopsy test for non-invasive cancer diagnosis and treatment monitoring. Analyzes circulating tumor DNA in blood to detect cancer-causing mutations and guide personalized oncology treatment decisions. Reduces need for invasive tissue sampling and enables frequent monitoring for treatment response assessment.

Assay system for detecting and quantitating cell-free DNA in liquid biopsy samples. Used in prenatal testing and cancer diagnostics with high sensitivity and multiplexing capabilities through the QLoci platform.

A qualitative diagnostic test for the detection of targeted 74 DNA mutation hotspots in non-small cell lung cancer (NSCLC) using circulating cell-free DNA (cfDNA). This assay enables advanced molecular testing for oncology applications.

Kit for extraction and purification of cell-free DNA from plasma samples. Enables non-invasive genomic analysis for rare variant detection and liquid biopsy applications.

Blood-based diagnostic test for monitoring cancer treatment efficacy and detecting emerging drug resistance through analysis of circulating tumor DNA. Enables rapid treatment adjustment decisions based on genetic mutation detection in cfDNA.

QLoci-based assay panel for non-invasive prenatal testing that identifies and quantitates fetal cell-free DNA (cfDNA) fragments. Provides genetic screening with minimal sample requirements and high sensitivity.

HCCscreen is a cancer early detection technology and service based on circulating free DNA (cfDNA) and blood biomarkers for hepatocellular carcinoma screening. Clinical data from 1,615 asymptomatic individuals demonstrated 88% sensitivity and 93% specificity, outperforming ultrasound screening which showed 71% sensitivity and 95% specificity. The service is available through hospital networks, government screening programs, physical examination centers, and online health platforms.

Adellgene® Fragile X is an in vitro diagnostic test for detection and diagnosis of Fragile X syndrome using Real Time PCR and fragment analysis. This genetic marker detection assay identifies triplet repeat disorders associated with FMR1 gene mutations, enabling accurate clinical diagnosis and carrier screening. The test supports genetic counseling and reproductive planning for affected families.

Custom NGS panels for targeted resequencing using Cell3 Target technology to convert cell-free DNA (cfDNA), genomic DNA (gDNA), and formalin-fixed paraffin-embedded (FFPE) DNA into libraries for next-generation sequencing. The panels are validated for ctDNA, gDNA, and FFPE DNA samples for oncology applications including early cancer detection and cancer monitoring. They incorporate error suppression technology with unique molecular indexes (UMIs) and unique dual indexes (UDIs) to enable confident variant calling down to 0.1% VAF, with support for as little as 1 ng of genomic or cfDNA input and 10 ng of FFPE material.

Proprietary circulating tumor DNA analysis platform offering high accuracy and sensitivity for early cancer detection. Provides precision diagnosis for personalized cancer management and monitoring.

DELISA is a highly sensitive digital ELISA analysis platform utilizing magnetic particle technology for multiplex immunoassay. It enables quantitative detection of disease biomarkers including vitamin D, Alzheimer's markers, and cardiac troponin for clinical diagnostics. The platform delivers comprehensive biomarker analysis with high sensitivity and specificity for laboratory and clinical settings.